The SBRT white paper was reviewed by 8 experts from the field of SBRT. All the comments were reviewed and discussed by the entire task group and appropriate revisions were incorporated in the paper with task group consensus.
It is important to understand that the SRS/SBRT QA measures described and recommended in this document are just one component of a broader process of ongoing quality assurance for the entire scope of practice within a radiation oncology department that includes periodic review of errors, incidents, and near misses for the purpose of developing or refining standard operating procedures that minimize the risk of such events.
Similarly, detailed equipment specifications and tolerances have been described in a number of documents, and while some of these aspects may be reiterated and/or emphasized in this paper, it is not intended to be comprehensive in this regard. Rather, this report builds on these and other documents, broadly addressing SRS/SBRT delivery with a primary focus on programmatic elements and human processes that can identify and correct potential sources of error, particularly those which can result in catastrophic consequences. One can make a distinction between quality improvement efforts and safety improvement efforts, but for this document, they are considered the same.
Nomenclature
The adjective "stereotactic" describes a procedure during which a target lesion is localized relative to a known three dimensional reference system. Stereotactic body radiation therapy (SBRT) and Stereotactic Radiosurgery (SRS) are specialized forms of cancer treatment whereby high doses of radiation are delivered in large fraction sizes over a short course of treatment, generally limited to 5 or fewer fractions. SRS is defined as treatment delivery to the brain or spine, while SBRT is defined as treatment delivery elsewhere within the body (which can include the spine); for completeness, fractionated stereotactic treatment for brain neoplasms is historically referred to as either stereotactic radiotherapy (SRT) or fractionated stereotactic radiotherapy (FSRT). These definitions SRS, SRT and FSRT are used to differentiate neurosurgical cases, which typically include participation of neurosurgical colleagues, from treatment of other sites where dose to nervous system structures is not a limiting normal tissue constraint. In contrast, the clinical activities of the radiation oncologist encompass the full range of disease sites, from brain to spine to body sites, with prescriptions from one to five fractions. The quality assurance and safety issues are similar for SRS and SBRT, and the acronyms are used somewhat interchangeably, though differences are highlighted where specific emphasis is required.
From the earliest days of radiosurgery, the use of a stereotactic head frame has been a prerequisite for accurate cranial localization. The head frame both defines the stereotactic space and provides the means for positioning and immobilizing the patient. While frameless techniques which incorporate image guidance can now provide equivalent accuracy for cranial applications, the use of a head frame remains widely used. In contrast, while SBRT localization may be assisted through the use of "body frames," final SBRT localization must be performed using a sophisticated form of 3-dimensional image guidance, tightly integrated with the delivery system, to confirm proper patient positioning and tumor localization within the reference space. To minimize intra-treatment tumor displacement associated with breathing or other motion, some method to address intra-fraction target movement is often required. This can take the form of passive motion management, such as the design of patient/respiration-specific target margins from 4D computed tomography (4DCT), or active motion management such as abdominal compression and beam gating/tracking. Management of respiratory motion is covered in detail in the report of AAPM Task Group 76 (1) . SBRT may be delivered in 1 to 5 fractions, and each and every fraction requires an identical degree of precision, target localization accuracy, and quality of image guidance.
SRS has been used for decades in the treatment of brain metastases and a variety of functional disorders, and its efficacy and toxicity profile has been well described as an efficient and effective means of achieving a high rate of local control and, in some settings, improved survival (2) . Acute side effects, including headache, pin-site infection, and short-term exacerbation of neurologic symptoms are relatively minor and readily managed. Late side effects, including radiation necrosis, brain edema, and exacerbation of preexisting, or development of new neurologic deficits occur in less than 5% of patients (3) . Five year local control rates following SRS or fractionated stereotactic radiation therapy (FSRT) for acoustic neuromas exceed 95% (4) . Current doses of 13 Gy (single fraction) or ~50 Gy (in 1.8 Gy fractions) yield excellent rates of hearing preservation as well as very low rates of facial and trigeminal neuropathies (4) . Similarly, excellent rates of local control can be expected following either SRS or FSRT treatment of meningiomas, though the grade and location of these tumors plays a significant factor in both tumor control and potential complications (5) (6) (7) . SBRT is a much more recent modality, with unique technological and clinical considerations. Nevertheless, initial clinical results from prospective single institution, and more recently, multi-institutional clinical trials of SBRT have documented similar high rates of tumor control coupled with a low incidence of serious toxicity despite the high dose fractions of radiation being delivered. The efficacy of SBRT is established for a variety of clinical indications as primary treatment for selected early stage cancers or as treatment for discrete tumors in patients with oligometastatic disease, selected benign neoplasms in or near the central nervous system, or recurrent cancer in previously irradiated regions. The utility of SBRT is perhaps best exemplified in the case of inoperable early stage lung cancer (8) , where the three year primary tumor control rate of 98% is roughly twice what would be expected from conventional RT given over a six to seven week period. To date reports of prospective clinical trials of SBRT have typically documented similar high rates of tumor control coupled with a low incidence of serious toxicity despite the high dose fractions of radiation given to tumors (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . This favorable therapeutic ratio is achieved because SBRT couples a high degree of anatomic targeting accuracy and reproducibility with very high doses of precisely delivered radiation, thereby maximizing the cell-killing effect on the target(s) while minimizing radiation-related injury in adjacent normal tissues.
Safety Concerns
Given that very high dose fractions of radiation are delivered, the margin of error for SRS and SBRT is significantly smaller than that of conventional radiotherapy and therefore requires special attention and diligence. A small error in target localization for any one fraction risks undertreatment of portions of the tumor by 20% or more. Inadvertent overdosage of adjacent normal tissues in even a single fraction could escalate the risk of serious injury to a much greater degree than an equivalent treatment error in a course of radiotherapy where a substantially lower dose per fraction is used (15, (20) (21) (22) (23) (24) . Low output factors associated with small fields necessitate delivery of a high number of monitor units, further increasing the associated risk.
Many in the community are aware of recent events, publicized in the media, in which serious errors have occurred. (25) (26) (27) , and 152 patients in Springfield, Missouri between late 2004 and late 2009; an error in a cranial localization accessory that affected seven centers in France, Spain and the U.S.; and errors in failure to properly set backup jaws for treatments using small circular collimators affecting a single AVM patient at an institution in France (26) , and three patients (at least one of whom received radiosurgery for trigeminal neuralgia) at an institution in Evanston, Illinois (28) . While no side effects related to the Florida calibration error have been reported, that is not the case with Elements of Successful SRS / SBRT Quality Assurance
Establishing Program Goals
It is important to emphasize that SRS and SBRT are not one treatment technique or modality. The implementation and accompanying requirements for immobilization, simulation, treatment planning, delivery and quality assurance can vary significantly with disease site. Clinical and technical proficiency for one site (e.g., spine) does not always translate to proficiency in another site (e.g., lung). This complex nature of the stereotactic treatment process, and the consequences of errors when delivering high dose fractions of radiation, mandates a systematic and prospective approach to each disease site. In 2008, a consortium of British organizations published a document entitled Towards Safer Radiotherapy (32) . Many of the overall recommendations are appropriate for SRS and SBRT programmatic development, including: a multidisciplinary working environment with a culture that fosters clear communication and guards against inappropriate interruptions; careful planning and thorough risk assessment when introducing new techniques and technologies; a review of staffing levels and skills, with specific training in each new treatment technique or process prior to clinical use. Training on specific technologies, often provided by the equipment vendor(s) is an essential training element. Vendor training by itself, however, does not provide the comprehensive instruction needed to competently perform SRS or SBRT. AAPM Task Group 101 has called for a thorough feasibility analysis of existing resources to achieve the clinical and technical goals of any proposed SBRT program (33) . Treatment of various disease sites should be considered within the context of nationally accepted clinical standards. It is strongly recommended that each department collect a library of published studies that document patient selection criteria and treatment planning and delivery parameters that are relevant to the population of patients to be treated with SBRT. Individual disease sites require unique and specialized technical elements and processes. Based on program goals and patient selection criteria, it is likely that treatment guidelines and procedures will be site-specific. Prior to initiating an SRS or SBRT program, this report strongly recommends that plans for patient selection and treatment guidelines be developed and clearly documented within each institution.
several of the other events. Gourmelon et al reported at 31% 12 month actuarial rate of trigeminal neuropathy in 32 acoustic neuroma patients overdosed in the Toulouse accident (27) . In contrast, despite a mean overdose of 61.2%, no treatment-related morbidity was observed in the 33 patients treated for brain metastases (25) . In the case of the French patient treated with the incorrect backup collimator setting, a subsequent dosimetric evaluation indicated that a large portion of normal brain received doses in excess of those intended for the AVM. The patient developed an oeso-tracheal fistula requiring surgery, experienced a hemorrhage and subsequently died (26) . One of the three Evanston patients is described as being in a vegetative state (28) . Radiosurgery errors are not limited to any particular technology. As an example, challenges in accurate measurement of output factors, such as those encountered on linacs in Toulouse, France and Springfield, Missouri, have also been encountered on gamma devices. In 1998, the output factor for a 4 mm gamma collimator was corrected by approximately 10%, from 0.80 to 0.87, by the manufacturer (29) (30) . A review of the Nuclear Regulatory Commission (NRC) Radiation Event Report Notification database yielded 13 gammabased radiosurgery-related events from 2005 to present, 12 of which resulted in a deviation from the original prescription. Seven of the events involved the treatment of the wrong location, while three events involved delivery of an incorrect dose. Wrong-site errors continue to plague all medical disciplines, and are not unique to radiotherapy (31) . While patient outcome is not described on the NRC site, several of the events listed, including treatment of the wrong location with single fraction doses as high as 90 Gy, would likely be accompanied by significant morbidity.
The accidents described can largely be attributed to human error, mirroring the radiotherapy experience throughout the United Kingdom, in which only 2 out of 181 incidents reported since 2000 were determined to be non-related to human error (32) . However, other factors also contributed. These include limits in equipment safety design and the inadequacy of systems and procedures to ensure that the stereotactic treatment was robust to the sources of error that eventually contributed to failure. Clearly then, improvement in human knowledge, training standards, and implementation of robust quality assurance processes is needed to minimize these errors, which in the case of SRS and SBRT, can have catastrophic consequences. A set of recommendations designed to guard against catastrophic failure in SRS and SBRT is provided in Appendix 1.
Personnel Requirements
SRS and SBRT require the coordinated efforts of a team of properly trained individuals who assume essential roles during the patient evaluation and treatment process (33) (34) (35) (36) . In addition to clinic nurses and other staff who provide general support for all patients receiving RT, for SRS / SBRT the essential personnel include the following individuals who have the indicated credentials and responsibilities: 2. The responsibilities of the radiation oncologist include management of the overall diseasespecific treatment regimen. The radiation oncologist will prescribe and supervise the means of patient positioning and immobilization, devices or techniques to manage any motion-related concerns, and simulation and planning image acquisition in the treatment position. The Radiation Oncologist must be provide direct supervision at the time of simulation, be present for critical decision making, and approve of the immobilization and imaging prior to completion of the simulation session. 3. The radiation oncologist is responsible for defining the target volumes, verifying image fusion and defining and approving the contours of all the critical normal structures (e.g., brachial plexus, trachea, spinal cord, etc.). The radiation oncologist works closely with the medical physicist and dosimetrist to design a treatment plan that provides proper dose to the tumor while respecting normal tissue dose constraints. 4. On the day(s) of patient treatment, the radiation oncologist must be present at the start of the treatment fraction (prior to irradiation) to verify the integrity of the patient setup at the treatment machine, patient repositioning using image guidance, and directly manage any clinical issues and/or treatment related toxicities. Thereafter, the Radiation Oncologist must be present for critical decision making and otherwise immediately available. SRS and SBRT require a high-precision of treatment delivery, use a wide range of technologies within and across institutions, and require a large resource commitment involved in patient care, quality assurance, and documentation. The personnel resources required for proper operation of an SBRT program would therefore be expected to be significantly larger than for a traditional radiation therapy program. AAPM Task Group 101 (33) and the AAPM-sponsored ABT surveys (37) provide some guidance on the additional physics personnel levels required for best-practice SRS and SBRT programs. Similar references should be developed to guide personnel decisions on the radiation oncologist, dosimetrist, and radiation therapist roles for SBRT. Nagata et al published the results of a recent survey of 53 institutions performing SBRT in Japan (38) . While practice patterns in Japan may differ from those in the United States, the document is nonetheless instructive for assessing resources needed to initiate and maintain a clinical SBRT program. Adequate levels of specialty staff is closely related to a reduction in medical errors (36, 39) . This report strongly recommends that institutions hire additional personnel to support SRS and/or SBRT programs. This report strongly recommends that the physician and physicist directing the initiation of the SRS and/or SBRT program consult with administration regarding the extent of additional resources needed to ensure safety. Institutions planning to begin an SRS or SBRT program must ensure they have adequately planned for the staff required to carry out all necessary tasks without undue pressure.
Radiation Oncologist

Technology Requirements
SRS and SBRT require the use of technology at a standard above that routinely considered necessary for conformal radiotherapy and initial image guided radiotherapy applications. The extreme demands imposed by the ablative paradigm of dose delivery amplify concerns over the volume of tissue irradiated to high doses as well as doses in serial organs and regions near the skin that may otherwise be ignored. To achieve these demands, small margins around the clinical target volume are necessary to such an extent that conventional radiographic localization based on bony anatomy is generally insufficient. A comprehensive image guidance and motion management strategy needs to be applied and maintained with sufficient technology and procedures to ensure safe and effective positioning for treatment. Furthermore, the dose distributions considered acceptable for SRS and SBRT require using large numbers of non-opposing beams often inclusive of multiple nonaxial approaches. Dose needs to be calculated accurately through complex heterogeneities and represented over the entire irradiated volume. Isocenter placement All personnel must demonstrate initial attainment of knowledge and competence in their respective discipline through graduation from an approved educational program, board certification and licensure as appropriate.
Initially
32-33
All personnel must receive vendor provided equipment -specific training prior to involvement in an SBRT program. 16 hours per staff member 32, 34
All personnel must receive disease-site-specific training prior to involvement in a stereotactic program. 16 hours per staff member 32, 34
All personnel must maintain their skills by lifelong learning through continuing professional development. For physicians and physicists this is the ABR Maintenance of Certification process. Ongoing 32, [34] [35] There must be adequate resources in place to meet the demands of the stereotactic program with sufficient staff. Staff must have sufficient time to carry out the necessary tasks without undue pressure.
Ongoing 32-33, 37, 39
Job description and list of responsibilities should be clearly delineated in writing for all stereotactic program individuals. Initially 32-33
Non-radiation oncology specialists can sometimes lend expertise in the area of target delineation for SBRT, given a deep fund of knowledge in the anatomy of various body sites. Examples of such specialists include neurosurgeons, pulmonologists, hepatologists, and oncologic surgeons.
Safety Considerations for SRS and SBRT 8 Safety Considerations for SRS and SBRT 9 Practical Radiation Oncology: August 2011 may be non-traditional due to needs of clearance for beam angles and imaging. Common technological and procedural requirements can be described by the SRS and SBRT processes.
Simulation
SRS/SBRT begin to deviate from conventional treatments at simulation. Immobilization, both physical as well as physiological, need to be devised as necessary. Images used for simulation and planning may require motion estimation (e.g. 4DCT), inclusion of soft tissue (MRI), or metabolic (PET) imaging. Paraspinal SBRT may require enhanced visualization of the spinal cord (e.g. through MR or CT myelography).
Typical immobilization equipment for SBRT includes custom formed devices that cover a large extent of the patient above and below the tumor (e.g., evacuated bean bags). The use of other technologies, such as surface imaging techniques, implanted radiographic markers and electromagnetic transponders may play a role in specific disease sites. For each of these devices and indications for use, the operational team (RTT, MD, physicist) should establish procedures for assessing the residual positioning uncertainty that is possible when combining these immobilization means with specific image guidance strategies.
4D CT or comparable imaging that is inclusive of the full range of motion of the target should be available for encompassing movement estimates into target volume construction. If gating, breath hold, or abdominal compression are to be used for treatment, then sufficient means must be available at simulation to image the patient appropriately for planning as well as to prepare for use, which includes an estimation of possible residual movement with any breathing management technique. Imaging must be performed over a sufficiently large volume to encompass the passage of non-axial beams through the patient.
Planning
The treatment planning environment must be capable of supporting both multimodality as well as multidimensional input data for SRS and SBRT planning. Specifically, MRI, PET, and multiple CT scans (e.g. non-contrast and contrast, 4D) must be able to be combined to facilitate target and normal tissue definition, establishment of a patient data set for use in image guidance, and generation of the appropriate density grid for dose calculation.
The planning system must be able to support dose calculation algorithms that represent dose deposition in the face of heterogeneities with sufficient accuracy. Commercial planning systems using pencil beam algorithms generally do not meet this requirement. Demonstration of calculation accuracy during the commissioning process, e.g. via an independent dosimetric check of a planned and irradiated phantom containing heterogeneities by an entity such as the Radiological Physics Center (RPC), is strongly recommended prior to initiating an SBRT program.
The dosimetric goal of stereotactic techniques, namely, confining the high dose region to the volume of interest while effectively minimizing peripheral dose, is optimally accomplished through the use of many non-overlapping beams which converge on the target. RTOG has described a compactness constraint, which consists of a volume encompassing the PTV + 2 cm (40, 41) . Meeting such a constraint generally requires a significantly larger number of beams (on the order of 10-12 beams) than typically used in conventional radiotherapy (4-6 beams). SBRT treatment delivered using a small number of beams has been associated with significant morbidity (42) . The addition of non-coplanar beams can substantially improve plan quality, in terms of dose compactness and OAR avoidance, though attention to potential gantry/couch/patient collisions is important when doing so.
Localization
SBRT requires image-guided localization. Ideally, this guidance should involve tumor-based positioning at the start of each treatment fraction. In the absence of direct tumor localization, reliable soft tissue surrogates, e.g., implanted fiducial markers, may be necessary as a means of estimating position. Conventional radiographic localization based on bony anatomy is generally insufficient to meet the precision demands of stereotactic treatments for soft tissue targets. Appropriate equipment for localization (e.g. cone beam CT or other 3D image-based method) must be used and maintained with sufficient quality assurance procedures to ensure the usefulness (image quality) and accuracy of positioning. In addition to end-to-end tests at commissioning of any new image guidance technology and procedure, daily (or more frequent if needed) validation of the image-to-accelerator geometric relationship must be implemented.
In addition to pre-treatment positioning, the management of intra-fraction patient body movement as well as physiological motions such as breathing must be accounted for. Some examples of such technologies include in-room surface monitoring systems, fluoroscopic observation, external gating systems, and external interventional mechanisms such as abdominal compression and active breathing control systems. Sufficient technology and procedures need to be in place, with sufficient quality assurance in support of their role for intrafraction monitoring, position correction, and/or gating.
SRS / SBRT Systems Acceptance and Commissioning
Acceptance testing and commissioning are essential technical components of an SRS/SBRT program that must be performed and documented completely and thoroughly prior to clinical application. Acceptance testing is performed in cooperation with an equipment vendor to ensure that the equipment is operating within stated specifications and in compliance with regulatory requirements. As SRS/SBRT requires a high level of precision in target and dose localization, it is necessary for vendors to demonstrate that capabilities are commensurate with the requirements of SBRT. Specific SRS/SBRT equipment requirements are provided in the report of AAPM Task Group 142, with clear specifications and tolerances as well as requirements for daily, monthly and annual quality assurance tests (43) . Further, acceptance testing must be performed in a manner that assesses both the individual and integrated components that comprise the SRS/SBRT process. Integrated, end-to-end testing is clearly emphasized in several guidance documents (33, 34, 43) . For example, immobilization, image guidance and management of organ motion are all essential elements of SBRT. It is important to demonstrate that components operate properly within an integrated process.
Commissioning is a more extensive process in which detailed measurements are performed to characterize every aspect of the operation of the equipment for its eventual clinical use. A common example of a commissioning task is the measurement of radiation data for subsequent use in dose calculation and treatment planning. Again, a critical aspect of commissioning is to verify the proper integration and operation of the various pieces of equipment that make up the combined SRS or SBRT system. This would include equipment and processes for CT simulation, treatment planning, treatment management systems (electronic radiotherapy record, including record-and-verify), image guidance and localization, and treatment delivery. Electronic treatment management systems in particular are an integral part of the radiotherapy process. Errors in configuring the treatment management system can be propagated through every treatment and patient. A complete commissioning process, therefore, must include thorough tests of the treatment management system.
Generally the commissioning task begins with the measurement of the radiation characteristics of a machine. Beam data acquisition is a common task performed routinely by medical physicists; the process has been described in detail in the report of AAPM Task Group 106 (44) . Acquisition of beam data for SRS and SBRT can be particularly challenging, however, due to the small size of the fields employed. There are several efforts aimed at improving accuracy and reducing errors in small field dosimetry, and addressing calibration issues in treatment modalities that cannot establish conventional reference conditions (45) . These include a recent publication by the Institute of Physics and Engineering in Medicine (IPEM) (46) and ongoing effort of AAPM Task Group 155.
Small field measurements require appropriately small detectors; TG 101 recommends the use of a dosimeter with an active area of 1 mm2 or less (33, 35) . Centering of the dosimeter in the beam is also challenging, and improper alignment of the beam and detector can introduce significant uncertainties. Further, small photon beams exhibit a loss of lateral electronic equilibrium on the central axis, producing output factors that falloff rapidly for fields below 10 mm in diameter (47) (48) . Due to the challenges associated with beam data acquisition, and the profound clinical consequences of wrong data that are now well known in the recent media, this report strongly recommends that steps be taken to independently assess small field measurements. This could include comparison against published data, comparison against un-published data from similar treatment units, or by verifying the data through a completely independent set of measurements. Similarly, independent verification of the absolute calibration, utilizing a service such as that provided by the Radiologic Physics Center (RPC), is essential.
Following beam data acquisition, the treatment planning system must be fully commissioned to ensure accurate calculation of dose and monitor units. This involves a systematic comparison of calculation and measurement, ranging from simple configurations, such as a single beam, to sophisticated arrangements of beams encompassing any and all situations encountered in clinical practice. Non-equilibrium effects are exacerbated at higher energies, and in the presence of low density tissue heterogeneities (49) (50) (51) (52) (53) . It is for these reasons that the RTOG excluded the use of energies above 10 MV, and field sizes smaller than 3.5 cm, in the initial lung SBRT trials (40) (41) . Deficiencies with some dose algorithms in accounting for non-equilibrium effects also led the RTOG to prohibit treatment planning using heterogeneity-corrected pencil beam algorithms; monitor unit calculations were required to be performed assuming only water density within the patient. The use of pencil-beam algorithms in lung SBRT applications where a target is surrounded by low-density tissue is also specifically disallowed in both AAPM Task Group reports 85 and 101 (33, 54) . In subsequent lung SBRT protocols, RTOG has mandated the application of heterogeneity corrections with sophisticated dose algorithms, including superposition/convolution or Monte Carlo (55) (56) . In contrast, the use of a PB algorithm is appropriate for cranial disease sites. In any event, commissioning must assess capabilities of the dose algorithm by incorporating appropriate, site-specific phantoms.
Other aspects of commissioning and quality assurance of treatment planning systems can be found in the report of AAPM Task Group 53 (57) . While the use of body frames has been described for localization purposes, these devices by themselves are inadequate for ensuring targeting accuracy at the level required for SBRT. Image guidance, utilizing volumetric techniques such as cone beam CT, or multiple 2D projections, is a prerequisite for SBRT localization (33, 34) . As such, thorough commissioning and systematic assessment of the random and systematic imaging errors are essential. It is important to evaluate end-to-end localization capabilities (simulate-plan-localize-treat), as well as individual imaging components, such that the information obtained by the imaging system properly directs the selected beams to the position within the patient determined by the treatment planning process. Guidance for commissioning and quality assurance of image guidance systems is described at length in AAPM reports 101 and 104 (33, 58) . SRS and SBRT require precise delineation of patient anatomy, targets for planning, and clear visualization for localization during treatment delivery. It is also during the simulation process that immobilization devices are constructed. As such, acceptance testing, commissioning, and quality assurance of CT simulators and other imaging modalities takes on added significance. Commissioning and quality assurance of the simulation process is described in length in the report of AAPM Task Group 66 (59) . Management of respiratory motion is a critical aspect of SBRT planning and delivery of moving tumors. Some mechanism must be provided to minimize or otherwise account for respiratory motion during the simulation and treatment process (33, 34, 40) . Several effective methods exist, including: abdominal compression, beam gating, tumor tracking, and generation of patient-specific margins using fluoroscopy or a 4DCT-based internal target volume (ITV). Available techniques and their proper use and application are described in detail in the report of AAPM Task Group 76 (1) . Ultimately, end-to-end localization and dosimetric capabilities must be demonstrated and documented prior to initiating clinical SBRT procedures. This is echoed in a number of documents (33) (34) (35) and stated very succinctly in the Canadian Association of Provincial Cancer Agencies (CAPCA) stereotactic radiosurgery/ radiotherapy standards (35) : "It is essential to recognize that commissioning SRS/T techniques involves more than just ensuring that the equipment itself works properly. The whole treatment chain, including the measuring, imaging modalities and treatment planning system must be tested in addition to the delivery unit and the SRS/T tools." In addition, acceptance testing and commissioning are also essential for establishing baseline parameters for quality control and improvement programs and processes. Documentation of procedures, as well as of specific work for each case, can be a very significant task, and should be considered as part of the time and effort needed in commissioning and maintaining an SBRT program. Table 3 below provides a suggested time frame for each of the critical commissioning steps. The overall process may be compressed, as several of the steps can be performed in parallel, depending on available resources. Comprehensive treatment planning system commissioning incorporating a full range of stereotactic delivery parameters and techniques, and specifically addressing use of inhomogeneity corrections with specific dose algorithm(s), must be performed prior to initiating a clinical stereotactic program.
4-8 weeks 33
Independent verification of system commissioning, utilizing appropriate specialized phantoms such as those from the Radiological Physics Center, should be performed prior to initiating a clinical stereotactic program and prior to initiating new clinical sites and/or treatment techniques.
2-4 weeks
Thorough commissioning of simulation devices and processes, including 4D CT if used, must be performed prior to initiating a clinical stereotactic program.
2-4 weeks 33
Management of respiratory motion is an essential element of SBRT simulation, planning and delivery. Measures must be developed to ensure effective and safe operation of these technologies.
2-4 weeks 33-34, 40
Evaluation of individual and end-to-end localization capabilities of the image guidance system must be performed prior to initiating a clinical stereotactic program and prior to initiating new clinical sites and/or treatment techniques.
weeks 33-34
End-to-end commissioning procedures, incorporating simulation, treatment planning and dosimetry, image guidance, management of motion, and treatment management systems, must be performed prior to initiating a clinical stereotactic program and prior to initiating new clinical sites and/or treatment techniques. In addition, users may find it useful to deliberately introduce known errors, and evaluate the capabilities of the system and processes in detecting such errors.
weeks 33 1TD Solberg et al
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Recommendation Duration or Frequency Reference
A department providing stereotactic services must have a formal quality management system, with documented policies, processes and procedures. In addition to ongoing quality improvement, quality management system should be reviewed internally in toto on a bi-annual basis.
Initially, and bi-annually thereafter 32-33
A department providing stereotactic services should be accredited by the ACR-ASTRO Radiation Oncology Accreditation Program.
Initially 34
An introduction to the individual treatment and QA processes, and to the goals and operation of the overall quality management system, should be part of the mandatory training for all staff. Initially 32
Specific equipment and patients QA procedures, tolerances and frequency should follow nationally accepted standards. Finally, as "the complexity, variation in individual practice patterns, and continued evolution of stereotactic-related technology can render a static, prescriptive QA paradigm insufficient over time (33) ," QA activities must continually evolve. Programs must adhere to a process of ongoing quality improvement, continually evaluating the adequacy of policies and procedures. Elements of an ongoing quality improvement process are discussed in Section 5 of this report.
The ongoing work of AAPM Task Group 100 will specifically address catastrophic failures and frequency and specifications for various tests, with in a landscape-changing paradigm based on estimates of failure modes (61) . It is anticipated that this approach will be well suited to SRS / SBRT quality and safety efforts.
SRS / SBRT Quality Assurance
General QA Concepts
In its 2000 landmark report, the Institute of Medicine (IOM) estimated that between 44,000 to 98,000 people die each year as a result of preventable medical errors (60) . Quality assurance is an essential aspect of every medical discipline, and the importance of a robust quality assurance program to reduce errors of all kinds cannot be overstated. In its Radiotherapy Risk Profile, the World Health Organization (WHO) states that proper QA measures are imperative to reduce the likelihood of accidents and errors and increase the probability that the errors will be recognized and rectified if they do occur (36) . ASTRO and ACR guidelines are equally clear with regard to SRS and SBRT QA: "Strict protocols for quality assurance must be followed (34) ." For radiotherapy, the WHO defines quality assurance as:
"…all procedures that ensure consistency of the medical prescription, and safe fulfillment of that prescription, as regards to the dose to the target volume, together with minimal dose to normal tissue, minimal exposure of personnel and adequate patient monitoring aimed at determining the end result of the treatment."
There are many essential elements to a successful quality assurance program. The following list, culled from several sources (32, 33, 36) , is intended to highlight the broad range of these elements:
• Foster an environment that ensures trust and encourages communication and collaboration among all program/institution staff.
• Strongly encourage staff to perform a "time out" before treatment is initiated, and at any time there is any question as to the integrity of the treatment; • Provide appropriate resources:
• provide adequate numbers of properly trained personnel; • provide time and opportunity for all staff to participate in continuing medical education; • provide ample time for staff to perform their required tasks, including QA tasks, without undue stress or fatigue; Safety Considerations for SRS and SBRT 13 Practical Radiation Oncology: August 2011
Equipment QA
Specific quality assurance processes and procedures will necessarily cover a broad range of stereotactic program elements, but generally can be grouped in two broad categories: equipment-related and patient-related. As with other delivery modalities, it is recommended for stereotactic programs to create daily, monthly and annual equipment quality assurance procedures.
Daily QA activities should be designed to verify the basic functionality and safe operation of the delivery and imaging equipment, especially the integrity of individual delivery and imaging devices, localization capabilities, and verification of the coincidence of imaging and therapeutic radiation isocenters of the treatment unit. Monthly QA procedures should be designed to detect trends in performance away from baseline and are focused on the imaging and delivery devices most likely to affect patient treatment. Annual QA procedures should be a thorough test of all aspects of the individual and integrated stereotactic system, including imaging, treatment planning, localization, R/V, and delivery devices and processes.
These QA procedures should be designed to detect any deviation from the baseline performance of the system determined at commissioning. AAPM Task Group 142 provides a comprehensive list of test, frequencies and tolerances for linear accelerator-based radiotherapy (43) . While all of the tests are relevant to linac-based SRS/ SBRT programs and must be performed accordingly, TG 142 provides more rigorous tolerances for those tests specific to SRS and SBRT treatments. These are summarized in Tables 5 below and 6 on the following page, supplemented and modified as needed. Several tests deserve additional discussion. First, a "Winston-Lutz" type of test provides the fundamental assessment of radiation isocenter and should be performed daily. Second, if image guidance is used for either cranial or extracranial localization, a test that verifies proper calibration and operation of those systems should also be performed daily. Finally, end-to-end tests of both localization and dosimetric capabilities should be performed to assess the accuracy and integrity of the SRS /SBRT processes in an integrated manner. This report recommends annual evaluation of these characteristics. The report of AAPM task group 101 provides a number of excellent references for guidance in performing these tests (33) . The report of AAPM task group 135 will provide specific guidance for QA of robotic radiosurgery devices. Similarly, the report of AAPM TG-148 describes QA for helical tomotherapy devices (62) . Table 5 . SRS / SBRT-specific linac-related quality assurance requirements, to be performed in addition to the standard linear accelerator tests described in the AAPM Task Group 142 report.
Daily Tests Procedure Tolerance
Laser Coincidence of radiation and mechanical isocenter ± 1 mm from baseline Verification of small field beam data -output factors, depth dose, and off axis profiles for cones and MLC ± 1% from baseline End-to-end localization assessment "hidden target test" using SRS frame and/or IGRT system ≤ 1 mm
End-to-end dosimetric evaluation using SRS frame and/or IGRT system ≤2% 
Patient / Process QA
In contrast to equipment quality assurance, for which specific tests and tolerances are well established, patientspecific QA spans a broad spectrum of activities, from assessment and decision to treat, to performing patientspecific phantom measurements prior to treatment, to identification of the proper patient at all stages of the process. The WHO has provided an excellent analysis of the risk categories inherent in the radiotherapy process: Each of these categories may contain many additional elements, each intended to ensure the highest level of care and reduce the risk of any error. A partial list of specific recommendation for patient-specific QA is provided in Table 7 on the following page. Many tasks are repeated a number of times over the course of treatment and the use of procedural checklists for all aspects of the process can be particularly effective at ensuring compliance and minimizing error. There is no substitute for redundancy in these checks, as independent human oversight provides significant opportunity to avoid simple mistakes from a single observer. Checklists to be used prior to daily treatment must be customized to the particular treatment planning and delivery systems available at the institution. Essential elements of a proper checklist include to be used on the day of treatment include, but are not limited to, the following: 
Recommendation Reference
The course of treatment, including dose schedule, normal tissue constraints, CTV/ITV and PTV margins, should follow established national guidelines, with careful consideration of the setup accuracy of the particular system in place at the given institution. Examples of dose constraints used at one institution are provided Reference 61.
33-34, 63
Treatment protocols that spell out responsibilities and detailed procedures ,must be available for all personnel, including therapists, medical physicists and radiation oncologists.
One or more comprehensive checklists should be used to guide all aspects of the treatment process. Examples of checklists used at several institutions are provided in Appendix 2 and 3. Note: these checklists intended to serve as a template, and should not be adopted in whole or in part. They are institution and technology specific are meant solely for illustration.
34-36
Appropriate program team members, including radiation oncologist(s), medical physicist(s) and radiation therapist(s) must be present as described by their responsibilities during the various aspects of the treatment process.
33-34
All imaging for anatomical definition / contouring purposes should be performed with the patient in the treatment position, and if possible, in the immobilization device to be used for treatment. 33
Patient-specific pre-treatment QA is considered necessary for a safe SBRT program. Prior to initiating treatment for each and every patient, the institution must verify that there is adequate information available to ensure that the process is correct. The QA methods used must verify the integrity of the data transfer from the treatment planning system to the treatment management system and the accuracy of the dose to be delivered.
33
Extra verification steps must be taken in cases where a laterality or adjacency errors could be made. This would include, for example, radiosurgery for trigeminal neuralgia, thalamotomy and pallidotomy, and spine SBRT.
An independent review of all planning, setup and treatment parameters must be performed prior to initiating treatment.
A radiation oncologist should be present at the treatment unit before irradiation to confirm localization based on reference images and review and approve the results of image guidance procedures prior to each treatment. A medical physicist must be present at the treatment unit before and during imaging, and through the entirety of each treatment to ensure that all issues of patient position, proper machine settings, and any technical issues of treatment delivery are safely and correctly applied. Procedures for image review and setup correction must be readily available for all personnel.
32-34
All images, corrections, and treatment parameters must be saved and available for subsequent review. If such information is not captured by the treatment machine / treatment management system, then it must be recorded manually. 32
Procedure Performed
Validate target construction, appropriateness of planning directives and normal tissue toxicity risks, establish immobilization, breathing management and image guidance strategy, validate plan and monitor units, ensure adequate image and structure information is provided to support localization method
Prior to first fraction
Validate initial setup instructions, check script against downloaded plan, ensure sufficient documentation, check validity of monitor units, supervise/assist patient positioning, verify delivery of treatment on site
At first fraction
Check validity of script and setup, assist in image guided localization, ensure adequately trained personnel familiar with the individual treatment are present to perform irradiation Prior to each fraction
Processes for ongoing quality improvement
AAPM Task Group 101 states, "A vital component of any comprehensive QA strategy should be to regularly review existing QA procedures with the objective to assess and critique the current QA practice in the context of current and proposed equipment." Ongoing quality and process improvement is important in SBRT not only for quality assurance procedures, but for all parts of the SBRT process and SBRT program as a whole. Commitment to ongoing process improvement activities help to ensure that an SBRT program sustains efficiency, effectiveness, and safety over time.
Quality improvement processes should include interval followup of all patients subsequent to their treatment, with interval durations determined in a site and diseasespecific manner. Regular QA process reviews should include audits of quality assurance tests to ensure they are correctly following procedures, as well as a review of the procedures themselves to increase effectiveness and The current guidance from ACR and ASTRO for IMRT patient-specific quality assurance recommends verification of the IMRT treatment plan parameters and the use of dosimetric measurements to verify the accuracy of the dose delivery. Due to safety considerations, these tests for acceptability must always be performed prior to the start of the patient's treatment with any given plan. This report strongly recommends a similar patient-specific QA process for SRS/SBRT, regardless of whether IMRT is employed. It is acknowledged, however, that there is variation in practice among institutions with respect to the content of pre-treatment QA programs along with the equipment and software used. This report therefore allows some latitude in this regard, providing that prior to initiating treatment or each and every patient, the institution takes steps to verify that there is adequate information available to ensure that the process is correct.
efficiency. External audits of stereotactic programs are strongly recommended. Offline monitoring and analysis of uncertainties and trends can help to detect systematic and emergent problems in equipment and treatment procedures. A commitment to formal feedback to vendors helps to tie institutional quality improvement processes into the vendor's own quality processes and guides future product development.
In addition, institutions providing SBRT services are encouraged to investigate formalized tools for process improvement such as process mapping, process control and fault-tree analysis. These tools can help take guesswork out of processes and can help analyze risk and mitigation strategies on a quantitative basis. (64) Proper ongoing quality improvement should at a minimum include interval follow-up of all patients subsequent to their treatment, offline monitoring and analysis of uncertainties and trends, periodic reviews, staff evaluations, and formal feedback to vendors.
Documentation
Proper documentation of all aspects of an SBRT program is essential to the program's success and is critical to any ongoing practice quality improvement (PQI) program. Documentation must occur at all levels of the program, including personnel, equipment commissioning and QA, patient and treatment-specific records, and offline analysis and monitoring of uncertainties and trends.
Documentation of personnel credentials, ongoing operational and safety training, time spent on any given task, and lifelong continuing education is important for ensuring the quality of the treatment team. Proper documentation makes it possible to remind team members if they are overdue on any required training or continuing education. It also allows the team to track resource allocations and detect a need for additional staff in any given area. Documentation of equipment commissioning and quality assurance processes and test results help ensure tests are performed in a repeatable, systematic way. They allow the team to detect emerging problems in the system that can then be remedied before they become severe. Documentation of service requests and resolutions help the team estimate reliability, budget repair costs, and detect systematic equipment deficiencies that need to be addressed. Offline monitoring of uncertainties and trends can help the team refine procedures and equipment usage patterns.
Patient-specific documentation should be in accordance with good medical practice as appropriate for the stage and site of disease treated. It should include clinical histories and treatment rationale, as well as treatment plans, setup notes, ongoing treatment records, patient-specific quality assurance checks, treatment modifications, etc. Proper documentation of patient follow-up examinations allows retrospective analysis for trends in treatment efficacy. AAPM Task Group 101 includes recommendations for specific data to document for SBRT treatments (33) .
Other Recommendations
While this report deals primarily with institutions and professional staff, there are many stakeholders in the QA process, with common goals and shared responsibilities. In this regard, improvement of patient safety would be facilitated by collaborative efforts between the manufacturers and the users. It is hoped that there will be increased discussions and interaction between manufacturers and users in designing safer systems, in developing QA methods and training programs, and in promoting patient safety for SRS and SBRT. There are many areas for collaborative efforts between equipment vendors and end users to enhance the patient safety aspects of SRS and SBRT systems. For example, there must be dialogue and communication between equipment manufacturers and end-users on the approaches, system design, QA methodology, and clinical implementation of SRS and SBRT. Vendors must understand the needs and requirements of the clinicians, medical physicists and radiation therapists relative to the systems and processes for SRS and SBRT. With such understanding they must exert all the necessary efforts to incorporate features and safeguards to assure efficacious and safe operation of their products. By the same token, the end-users need to work with the manufacturers in developing commissioning, safety and quality assurance tools, programs and procedures for the SRS and SBRT systems.
There are many steps equipment vendors can take to improve the safety of their systems. Adequate training of all the SRS/SBRT team members, in their respective areas of responsibilities, is of paramount importance. Vendors must provide additional opportunities for specialized training, emphasizing implementation, clinical and quality assurance in addition to technical aspects, and the home institution must make available resources and time for such training. It is not adequate to train users on the basic aspects of system operation if the systems are sold and used to specialized purposes such as SRS and SBRT. Vendors must do more to emphasize all QA aspects, not only equipment QA, but process QA. SRS / SBRT systems consist of multiple components, and vendors must ensure and demonstrate full mechanical, electronic and information connectivity of these components. In situations where components or subsystems come from more than one manufacturer, it is the responsibilities of the manufacturers to collaboratively demonstrate compatibility of the various subsystems, and their safe operation when used in combination. The users must assure that such demonstration are documented and are satisfactory in terms of safe SRS and SBRT implementation. Departments must remember that the final responsibility of safe operation of complex treatment technology and procedures lies with the department, and that vendor documentation is only one part of the safety process. Adequately trained staff, with sufficient time, resources and support, are critical to implementation of stereotactic procedures with modern technology.
Finally, while a turn-key approach to the use of complex clinical systems is appealing in terms of procedural simplicity, inadequate understanding of the internal workings of such complex systems by the endusers is of concern. Rather, vendors should take an "allinclusive" approach of safe equipment design, understanding the need for QA equipment and procedures, and emphasizing commissioning, safety and quality assurance requirements and procedures.
Professional organizations must do more to facilitate proper training in specialized procedures such as SRS and SBRT, and to ensure that only qualified practitioners are involved in such procedures. Specialized accreditation programs may be an effective mechanism to realize this. The American College of Radiology presently accredits several imaging specialties, including CT, MRI mammography and stereotactic breast biopsy. Extending accreditation to SRS and SBRT would be a strong step in emphasizing and recognizing quality practices. The current ACR-ASTRO Radiation Oncology Accreditation Program of radiation oncology practices should no longer be voluntary.
There are many steps that government agencies can take to enhance safety within the profession. There are numerous inconsistencies in regulation and radiation event reporting between state and federal agencies, and with regard to radioactive versus x-ray sources. The findings of an earlier investigation on regulatory reform in radiation medicine pointed to the need for improved databases on the actual incidence of adverse events and severe misadministrations (65) . Such a system is mandated by law in the United Kingdom. Centralized registries for event-reporting, ensuring appropriate transparency regarding event details, are an effective mechanism for all stakeholders to learn from mistakes. Several voluntary efforts currently exist, notably the Radiation Oncology Safety Information System (ROSIS) (66) and the system implemented at Washington University by Sasa Mutic and colleagues (67) .
Summary
In summary, SRS and SBRT require a team-based approach, staffed by qualified radiation oncologists, medical physicists, and radiation therapists. Other specialists, including disease-site-specific physicians, may also participate as needed. Treatment of SRS / SBRT patients should adhere to established national guidelines. Appropriately trained radiation oncologist(s), medical physicist(s) and radiation therapist(s) should be present at specified components of, if not for the entire duration of, each SBRT treatment.
SRS and SBRT require significant resources in personnel, specialized technology, and implementation time. A thorough feasibility analysis of resources required to achieve the clinical and technical goals must be performed and discussed with all personnel, including medical center administration. Because various disease sites may have different clinical and/or technical requirements, feasibility and planning discussions are needed prior to undertaking new disease sites.
Program personnel must be certified in their particular specialty by a national certifying board, and licensed and credentialed as appropriate. Program personnel should maintain their certification and keep licenses and credentials current. Professional organizations are encouraged to develop specialized SRS / SBRT accreditation programs, similar to ACR-ASTRO Radiation Oncology Accreditation Program for specialty imaging programs.
Specific training in clinical and technical aspects of SRS and SBRT will become increasingly important in the future. SRS and SBRT training should become a required part of radiation oncology residency training and of (CAMPEP-accredited) clinical medical physics training. Current practitioners are strongly encouraged to participate in ASTRO and/or AAPM-sponsored SRS and SBRT CME prior to treating patients. This should include general SRS / SBRT training, as well as specific training in each disease site in which a stereotactic approach is used. Proctoring is an essential component of SRS and SBRT training. Program personnel must participate in continuing medical education specific to SRS and SBRT.
Acceptance and commissioning protocols and tests must be developed to explore in detail every aspect of the system with the goal of ensuring safe and effective operation.
A comprehensive quality assurance program, encompassing all clinical, technical and patient-specific treatment aspects, must be developed to ensure SRS and SBRT are performed in a safe and effective manner. Plan Evaluation:
• To find R100 (5400cGy) Volume (body) that receives prescription dose divided by PTV volume.
• To find R50 (2700cGy) Volume(body) that receives half prescription dose divided by PTV volume.
• All plans should meet dose constraints. If not, the physician needs to be informed during plan evaluation.
• Dose constraints change constantly so it is important to have the most current dose constraints. Attached is the most current dose constraint sheet. 
